Sarah Nayebosadri, PA
Surgical · Duluth, GANPI 1164916938
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 75.6% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $13,410, more than ten times the $1,006 reported in 2021. Among surgical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $94.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Teleflex LLC$2K
- Sumitomo Pharma America, Inc.$1K
- Johnson & Johnson$745
- Dendreon Pharmaceuticals LLC$423
- Endo Pharmaceuticals Inc.$355
- plus $3K from 30 others
Across 1 payment — averaging $140.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$140
What the payments were for
- Consulting fees$6222%
- Speaking & faculty fees$9,81335%
- Travel & lodging$7,95328%
- Food & beverage$9,48334%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 142 | $21,108 |
| Teleflex LLC | 16 | $1,633 |
| Sumitomo Pharma America, Inc. | 28 | $1,138 |
| Johnson & Johnson | 10 | $745 |
| Dendreon Pharmaceuticals LLC | 8 | $423 |
| Endo Pharmaceuticals Inc. | 9 | $355 |
| Coloplast | 8 | $340 |
| Ferring Pharmaceuticals Inc. | 11 | $261 |
| Myovant Sciences Inc. | 5 | $206 |
| Bayer | 5 | $169 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $145 |
| Astellas Pharma US Inc | 4 | $139 |
| Verity Pharmaceuticals Inc. | 6 | $129 |
| Myriad Genetic Laboratories, Inc. | 2 | $128 |
| Antares Pharma, Inc. | 6 | $108 |
| Amgen | 1 | $91 |
| Baxter Healthcare | 1 | $81 |
| Convatec Inc. | 3 | $69 |
| Urovant Sciences Inc | 3 | $65 |
| Endo USA, Inc. | 3 | $64 |
| Tolmar, Inc. | 3 | $64 |
| Tolmar Pharmaceuticals, Inc. | 3 | $59 |
| Halozyme Inc | 3 | $59 |
| Merck | 2 | $44 |
| Pfizer | 2 | $44 |
| Urogen Pharma, Inc. | 1 | $32 |
| Vertex | 1 | $29 |
| Ambu Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $28 |
| Novartis | 1 | $26 |
| Blue Earth Diagnostics | 1 | $25 |
| AstraZeneca | 1 | $23 |
| Davol Inc. | 1 | $21 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Rochester Medical Corporation | 1 | $19 |
| Olympus America Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,935 in reported general payments places this provider in the 95th percentile of 372 surgical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 108 | $94,685 |
| MyrbetriqMirabegron | 82 | $53,608 |
| XyostedTestosterone Enanthate | 11 | $6,251 |
| Methenamine Hippurate | 65 | $3,877 |
| Estradiol | 57 | $3,252 |
| Cefdinir | 48 | $746 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 46 | $545 |
| Trospium Chloride | 15 | $246 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $245 |
| Tamsulosin Hcl | 32 | $181 |
| Finasteride | 16 | $174 |
| Cephalexin | 15 | $157 |
| Fluconazole | 27 | $91 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $82 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $1,138 | $94,685108 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $53,60882 claims |
| Antares Pharma, Inc.Xyosted | $108 | $6,25111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 372 surgical providers in Georgia.
Other surgical in Duluth
- Lauren EdekerAlpharetta$305K
- Michael BerkeAtlanta$242K
- Emily WatsonAtlanta$150K
- Beretta Craft-CoffmanCanton$30K
- Kenneth NorrisLawrenceville$19K
- Scott LinacreLawrenceville$19K
- Richard HeimbeckerLawrenceville$15K
- Steven SnipesAlbany$14K
- Jessica SheppardSnellville$12K
- Janelle ShahStockbridge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.